Human trials begin on Alzheimer’s disease immunization

LOS ANGELES • Cedars-Sinai Medical Center has launched a Phase I clinical trial to study the safety and tolerability of an experimental immunization to treat Alzheimer’s disease.

The treatment is based on Copaxone (glatiramer acetate), a drug often prescribed to reduce the frequency of multiple sclerosis relapses.

“In mouse models of Alzheimer’s, immune-modulation with Copaxone appeared to stimulate key immune cells, reduce harmful inflammation, clear toxic plaques and support the restoration of neurons in a region of the brain that is responsible for learning and memory,” said Dr. Patrick D. Lyden, chair of the Department of Neurology. “We’re now translating these findings into human studies and this first trial will evaluate the medication’s safety and tolerability in patients suffering from Alzheimer’s.”

To read more…